Shots: Exact Sciences enter into a merger agreement with Genomic in cash & stock transaction for $72/share making the total deal value $2.8B. Genomic to receive $27.50 in cash & $44.50 in shares of Exact Sciences stock for each owned share based on the closing price value as of Jul 26, 2019. The transaction is […]Read More
Tags : New Cancer Diagnostics Company
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US